Creating the Next Wave of Multifunctional Antibodies
RECENT NEWS:
Key milestone achieved with first patient dosed with ARC101, the company's lead T cell engager program
We Are Innovating Along the Third Arc of Antibody Therapeutics
Our company is advancing the next major wave of antibody technology which we call the "Third Arc." During the
Third Arc Bio's approach unlocks the powerful biology of immune synapses to address large unmet need in complex disease areas like solid tumors and immunology and inflammation (I&I).
